Overview
RXST market data
Price History
RXST price chart · 1M
- O
- 6.32
- H
- 6.68
- L
- 6.31
- C
- 6.60
- Vol
- 33,694.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $6.32
- Previous Close
- $6.38
- Day High
- $6.68
- Day Low
- $6.31
- 52 Week High
- $7.49
- 52 Week Low
- $4.52
- 7 Day Return
- +8.37%
- 30 Day Return
- +8.91%
- 90 Day Return
- +24.06%
- 1 Year Return
- -3.44%
- Daily Notional Volume
- $222.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.95 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -36.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.48 – $13.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $291.6M · P/B 1.55 · P/S 2.29.
Company News
Stifel Maintains Hold on RxSight, Lowers Price Target to $7Benzinga · Aug 10, 2026, 12:31 PM
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3Benzinga · Aug 6, 2026, 7:39 PM
RxSight Q2 Adj. EPS $(0.11) Beats $(0.33) Estimate, Sales $33.741M Beat $32.547M EstimateBenzinga · Aug 5, 2026, 8:08 PM
8-K filing — RxSight, Inc. (RXST)SEC EDGAR · Jul 15, 2026, 8:23 PM
RxSight Appoints Aziz Mottiwala President, CEO, Effective July 20, Succeeding Ron KurtzBenzinga · Jul 15, 2026, 8:16 PM
B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $6.5Benzinga · Jul 7, 2026, 5:25 PM
Stock Market Today: Dow Jones Futures Gain, S&P 500, Nasdaq 100 Slips As SpaceX Debuts On The Exchange—Rivian, Micron In Focus (UPDATED)Benzinga · Jul 7, 2026, 12:40 PM
RxSight Sees Q2 Sales $32.000M-$34.000M vs $32.077M EstBenzinga · Jul 6, 2026, 8:55 PM
RxSight Raises FY2026 Sales Guidance from $120.000M-$135.000M to $140.000M-$160.000M vs $129.250M EstBenzinga · Jul 6, 2026, 8:55 PM
RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160MBenzinga · Jul 6, 2026, 8:20 PM